Form 4: Voyager Therapeutics CEO Awarded Equity Incentives

Voyager Therapeutics' President and CEO, Alfred Sandrock, was granted 86,250 restricted stock units and 402,500 stock options.

Summary

• Alfred Sandrock, President and CEO, and a Director of Voyager Therapeutics, Inc. (VYGR), was granted equity awards on February 6, 2026.
• The awards include 86,250 shares of common stock in the form of Restricted Stock Units (RSUs) at a price of $0.00 per share.
• These RSUs will vest over three years, with one-third vesting on the one-year anniversary of the grant date and an additional one-third vesting at the end of each successive one-year period, subject to continued service.
• Additionally, Sandrock was granted 402,500 stock options with an exercise price of $3.68 per share, expiring on February 6, 2036.
• These stock options will vest over four years, with 1/48th vesting on the one-month anniversary of the grant date and an additional 1/48th vesting at the end of each successive one-month period, subject to continued service.
• Following these transactions, Sandrock beneficially owns 522,181 shares of common stock and 402,500 derivative securities (stock options).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies continued commitment and alignment of the CEO's interests with long-term shareholder value through equity incentives.

Positives

• The equity grants align the interests of the President and CEO with those of shareholders, incentivizing long-term performance and value creation.
• The awards are part of a structured incentive plan, indicating a commitment to retaining and motivating key leadership.

Future Outlook

The vesting schedules for both the RSUs and stock options extend over multiple years, indicating an expectation of continued service from the President and CEO and a long-term incentive structure.

Industry Context

StockSavvy.ai notes that equity-based compensation, such as restricted stock units and stock options, is a standard practice across the biotechnology and pharmaceutical industries to attract, retain, and incentivize executive talent. These grants are typically tied to long-term performance and continued service, aligning management's financial interests with shareholder value.

Comparison to Industry Standards

• Equity grants to executive leadership are a common compensation component in the biotechnology sector, similar to practices at companies like Biogen or Sarepta Therapeutics, aiming to align executive incentives with long-term shareholder value.
• The multi-year vesting schedules for both RSUs (3 years) and stock options (4 years) are consistent with industry norms designed to promote executive retention and sustained performance.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grants are intended to align the CEO's long-term interests with shareholder value creation, potentially leading to more focused strategic decisions.
• Employees: The existence of a stock incentive plan and employee stock purchase plan indicates a broader framework for employee equity participation.

Next Steps

• The Restricted Stock Units will vest over three years, with 1/3rd vesting on the one-year anniversary of February 6, 2026, and subsequent annual vesting.
• The Stock Options will vest over four years, with 1/48th vesting on the one-month anniversary of February 6, 2026, and subsequent monthly vesting.

Key Dates

Keywords

Voyager Therapeutics, VYGR, Alfred Sandrock, Restricted Stock Units, Stock Options, Executive Compensation, Insider Transaction, Equity Grant, Form 4